Disc Medicine (IRON) Director Kevin Bitterman Sells 1,689 Shares

What Happened

• Kevin Bitterman, a director of Disc Medicine (IRON), sold a total of 1,689 shares in open-market/private sales on September 4, 2026. The transactions were: 912 shares ($72,924), 759 shares ($60,690) and 18 shares ($1,439), for an aggregate proceeds of approximately $135,053. These sales were reported on a Form 4 filed September 9, 2026. The sales are coded as S (sales) and were executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-09-04; Form 4 filed: 2026-09-09 (filed 5 days after the trades).
• Price: weighted average $79.96; reported trade prices ranged from $79.95 to $79.98. The filer will provide per-price breakdown on request (footnote).
• Shares sold: 912, 759, and 18 (total 1,689).
• Total value: ~$135,053 (sum of reported proceeds).
• Holdings after transaction: Not specified in the filing.
• Notable footnotes:
  • Sales were made pursuant to a Rule 10b5-1 trading plan adopted July 30, 2026 (F1).
  • Price shown is a weighted average; detailed per-price counts available on request (F2).
  • The sold shares were held by three Atlas Venture funds (Opportunity I, Opportunity II, and Atlas XII); Bitterman disclaims beneficial ownership of those fund-held securities except to the extent of any pecuniary interest (F3–F5).
• Timeliness: The Form 4 appears to have been filed late (filed five days after the trade). Late filings reduce transparency and can attract regulatory attention.

Context

• Sales made under a 10b5-1 plan are typically pre-scheduled and generally viewed as routine disposition rather than an immediate signal of changed insider sentiment. The filing’s footnotes indicate these shares were held by venture funds (institutional vehicles) for which the reporting person is affiliated; he disclaims direct beneficial ownership except for any economic interest.